Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder

Pharmacotherapy

Volumn 30, Issue 2, 2010, Pages 127-135

  Miceli, Jeffrey J ^a   Tensfeldt, Thomas G ^a   Shiovitz, Thomas ^b   Anziano, Richard ^a   O'Gorman, Cedric ^a   Harrigan, Rachel H ^a  

^a PFIZER INC   (United States)

^b California Neuroscience Research Medical Group Inc   (United States)

Author keywords

Antipsychotic; Drug concentration; Haloperidol; QTc interval; Ziprasidone

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; BENZATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DRUG METABOLITE; HALOPERIDOL; LORAZEPAM; METHYLDIHYDROZIPRASIDONE; NEUROLEPTIC AGENT; PARACETAMOL; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZIPRASIDONE; ZIPRASIDONE SULFOXIDE; ZOLPIDEM;

ABNORMAL VISION; ADULT; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EVENING DOSAGE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HOSPITAL PATIENT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MORNING DOSAGE; MUSCLE HYPERTONIA; NAUSEA; OPEN STUDY; OUTPATIENT CARE; PARALLEL DESIGN; PREDICTION; PROSPECTIVE STUDY; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TREMOR; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAM PATTERN; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES;

EID: 75849147334     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.2.127     Document Type: Article

References (22)

1. Pfizer Inc. Geodon (ziprasidone) prescribing information. New York, NY; 2006.
2. Moss AJ. QTc prolongation and sudden cardiac death: the association is in the detail. J Am Coll Cardiol 2006;47:368-9.
3. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362-7.
4. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003;17:423-30.
5. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:1625-33.
6. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43(5 suppl 1):1-45.
7. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-41.
8. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L - type calcium currents. FEBS Lett 2002;512:59-66.
9. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with QT interval prolongation. Am J Health Syst Pharm 2008;65:1029-38.
10. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71.
11. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
12. Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 2001;41:1310-18.
13. Correll CU, Frederickson AM, Figen V, et al. The QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci 2009;259:23-7.
14. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9.
15. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with highpotency and low-potency neuroleptics. Am J Psychiatry 1984;141:748-52.
16. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208.
17. Citrome L, Jaffe A, Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr Serv 2007;58:11.
18. Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 2005;25:388-91.
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
20. Strom BL, Faich GA, Reynolds RF, et al. The ziprasidone observational study of cardiac outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psychiatry 2008;69:114-21.
21. Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy [online exclusive article]. Ann Gen Psychiatry 2005;4:1. Available from http://www.annals-general-psychiatry.com/content/4/1/1.
22. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003;82:282-90.